Characteristics of the participating studies: Sub-Saharan Africa (26 studies).

aOnly Series 1 (n = 378) was included in the review. Series 2 is a replicate sample (n = 129) which was excluded because of a) potential overlap with other studies included in the review; and b) the number of ER+, PR+ and HER2+ known was not reported.bMethods for PR and HER2 testing are provided in the paper but no estimates for these two receptors are given.AJCC, American Joint Committee on Cancer; BC, Breast cancer; IBC, inflammatory breast cancer; IDC, invasive ductal carcinoma; ICH, immunocytochemistry; MR, medical records; n/a, not applicable; NK, not given in the paper; NOS, not otherwise specified.Characteristics of the participating studies: Sub-Saharan Africa (26 studies).